Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05669079 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 9, 2023 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 1, 2026 to Aug 1, 2026
    • Start date: Feb 1, 2023 to Aug 1, 2023
    • Study completion date: Jun 1, 2026 to Nov 1, 2026
    • Eligibility criteria shortened, about 2 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized trial aimed at validating the efficacy and safety of low-dose decitabine, together with umbilical cord blood in PGF post allo-HSCT patients.
Trial Details
NCT Number NCT05669079
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions
(from sponsor)		 Poor Graft Function
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov